Navigation Links
Pieris Announces Results and Successful Completion of its PRS-050 Anticalin Phase I Trial at AACR-EORTC-NCI Molecular Targets and Cancer Therapeutics Conference
Date:11/15/2011

SAN FRANCISCO, November 15, 2011 /PRNewswire/ --

Pieris AG presented the results of the Company's first clinical evaluation of its most advanced Anticalin®, PRS-050, an anti-VEGF targeted protein therapeutic, at the 2011 AACR-NCI-EORTC International Conference held in San Francisco, California.  The dose-escalation trial investigated the recommended Phase II dose, safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of PRS-050 administered to patients with advanced solid tumors.  PRS-050 was well-tolerated, with no maximum tolerated dose reached, while demonstrating biological activity and a complete lack of immunogenicity, supporting further evaluation in a Phase II clinical trial.  

"The Phase I results not only confirm the safety and tolerability of PRS-050, but also are indicative of an attractive safety profile for Anticalins generally," said Dr. Laurent Audoly, Chief Scientific Officer for Pieris AG.  "Moreover, the results of our PK/PD strategy provide human data supporting the robustness of our drug platform.  The Anticalin approach, which in this case, plays on monovalent target engagement, small size and the lack of an effector function, is well-suited for a biobetter VEGF-targeted therapeutic protein approach to treat several types of cancer."

The Phase I clinical trial of PRS-050 was conducted in 26 patients with advanced solid tumors as an open-label, dose-escalating evaluation of the compound's safety, tolerability, and PK/PD profile.  The protein drug exhibited a half-life of six days, there was no immunogenicity (no anti-drug antibodies) observed across all cohorts and multiple dose-dependent PD effects were obtained.  PRS-050 is an anti-VEGF (Vascular Endothelial Growth Factor) 40 kD PEGylated Anticalin discovered and developed internally at the company.  VEGF has a well-defined role in cancer angiogenesis, which is the mechanism by which cancer tumors increase blood vessel development at the tumor site and thereby enable further growth.  The compound began the clinical trial at three different sites in Germany during the first half of 2010.

The results were presented on Sunday, November 13th, 2011 at the American Association Cancer Researchers-National Cancer Institute-European Organization for Research and Treatment of Cancer International Conference on Molecular Targets and Cancer Therapeutics: Discovery, Biology and Clinical Applications is taking place November 12-16, 2011 at the Moscone Center West in San Francisco, California.

Anticalins are therapeutic proteins derived from human lipocalins, rationally engineered to solve for the pharmacological and pharmaceutical limitations of both protein and non-protein based drug platforms.  

About Pieris AG

Pieris AG is an independent, clinical-staged biotechnology company advancing its proprietary Anticalin® technology to create differentiated drugs that are safer and more effective than conventional approaches.  Exclusive to Pieris, Anticalin-based drugs promise to address high-unmet medical needs and expand the therapeutic potential of current targeted approaches. Pieris' pipeline ranges from its Phase I compound, PRS-050 (anti-VEGF, oncology), to multiple Anticalins in preclinical development across a range of therapeutic areas.  The company has four ongoing discovery and development collaborations: Daiichi Sankyo, Takeda San Francisco, the Sanofi Group and Allergan.  Privately held, Pieris has been funded by premier biotechnology-focused venture capital, including lead investors OrbiMed Advisors and Global Life Science Ventures. For more information, please visit: http://www.pieris-ag.com.

For further information, please contact:
Dr. Laurent Audoly, CSO
Pieris AG
or
Gretchen Schweitzer
+49-172-861-8540
media@pieris-ag.com

Further information is available at http://www.pieris-ag.com  

Anticalin®, Anticalins® are registered trademarks of Pieris AG.



'/>"/>
SOURCE Pieris AG
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Pieris Reports Development Progress for Anticalin(R) PRS-050, a Next Generation VEGF Antagonist
2. Wacker Validates Scalability of Anticalin(R) Production With E.coli Secretion Technology and Will Produce Pieris First Clinical Candidate PRS-050
3. China Medical Technologies Announces Payment on Maturity and Cancellation of its 3.5% Convertible Senior Subordinated Notes due November 15, 2011
4. Express Scripts, Inc. Announces Pricing of $4.1 Billion Senior Notes Offering
5. MedClean Technologies Announces Third Quarter Results
6. Landauer, Inc. Announces Acquisition of IZI Medical Products, LLC
7. Pregis Announces Third Quarter 2011 Financial Results
8. Radient Pharmaceuticals Announces FY 2011 Third Quarter Results
9. Dynatronics Announces First Quarter Results
10. Prometheus Announces New Chief Medical Officer
11. BioMed Realty Trust Announces Public Offering Price for 22,562,922 Shares of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... Research and Markets has announced the addition of the ... report to their offering. ... The Global Cryostat Market is poised to grow ... reach approximately $3.5 billion by 2025. This industry report ... on global as well as regional levels presented in the research ...
(Date:3/23/2017)... , Mar. 23, 2017 Research and Markets ... Market: Analysis By Procedure, Replacement Procedure By Technique, Repair Procedure By ... ... Valve Devices Market is forecasted to grow at a CAGR of ... devices is driven by rising aging population, growth in population with ...
(Date:3/23/2017)... INDIANAPOLIS , March 23, 2017  Eli ... the William Sansum Diabetes Center have established a research ... by diabetes through enhanced research, education and care. ... disease bears a disproportionate weight on Latino families in ... David Kerr , M.D., FRCPE, director of Innovation and ...
Breaking Medicine Technology:
(Date:3/24/2017)... ... March 24, 2017 , ... Infectious disease ... hospitals in the United States, it’s a threat that is constantly changing and ... infection prevention and offers strategies for the healthcare community to help decrease the ...
(Date:3/24/2017)... TX (PRWEB) , ... March 24, 2017 , ... ... clinic which can be found at 9618 Huebner Road. The clinic is the group’s ... OCS, Clinic Director, and Dr. Ali Higgins, PT, will provide care from the clinic, ...
(Date:3/24/2017)... ... March 24, 2017 , ... In ... innovative EcoQube Frame vertical micro-veggies garden on Kickstarter . Surpassing the $100,000 ... – with nearly 2,000 consumers (and counting) already backing the campaign. , ...
(Date:3/24/2017)... Westchester County, NY (PRWEB) , ... March 24, 2017 , ... ... in Somers and White Plains, N.Y., is pleased to announce Westchester resident Lauren C. ... as a law clerk for the firm, will concentrate her practice in elder law, ...
(Date:3/24/2017)... ... 24, 2017 , ... Judy Buchanan, co-owner of Serenity Natural ... Judy says, “I am passionate about sharing Reiki as a holistic, complementary therapy ... challenging time.” , A Certified Medical Reiki™ Master trained by Raven Keys Medical ...
Breaking Medicine News(10 mins):